文献速递肝病

SALT-M评分对亚洲慢加急性肝衰竭患者临床结局的稳健预测性能

Robust Predictive Performance of the SALT-M Score for Clinical Outcomes in Asian Patients With Acute-on-Chronic Liver Failure.
PubMed 文献 · Aliment Pharmacol Ther · 2024-10-11

在224例ACLF 2-3级亚洲单中心队列中验证SALT-M评分预测肝移植后1年生存的性能。SALT-M的AUROC为0.691、c-index为0.650,均高于MELD、MELD-Na、MELD 3.0和delta-MELD。按SALT-M≥20和MELD≥30分组,高SALT-M组移植后生存率低于低SALT-M组,ACLF 3级患者中SALT-M可有效分层移植后死亡率。

要点

  • SALT-M预测1年移植后生存的AUROC为0.691,c-index为0.650,均优于MELD系列评分。
  • 高SALT-M组移植后生存率低于低SALT-M组,不受MELD高低影响(p<0.001)。
  • ACLF 3级患者中,高SALT-M组移植后死亡率为39.4%,低SALT-M组为63.1%(p=0.018)。

核心结论

  • SALT-M评分在亚洲严重ACLF肝移植队列中预测移植后死亡率优于既往MELD系统。
  • 严重ACLF患者的移植可行性可基于SALT-M评分判定。

研究设计与样本

  • 在大型亚洲单中心队列中验证SALT-M评分,共分析224例ACLF 2-3级患者。
  • 使用AUROC和一致性指数(c-index)评估并比较SALT-M与其他评分对移植后死亡率的预测能力。
  • 比较高SALT-M与低SALT-M患者的生存率,并结合MELD评分和ACLF分级进行分析。

主要发现

  • 预测1年移植后生存的AUROC:SALT-M为0.691,高于MELD、MELD-Na、MELD 3.0和delta-MELD。
  • c-index:SALT-M为0.650,高于上述MELD系统。
  • 按SALT-M≥20和MELD≥30分组,移植后生存率:高SALT-M/高MELD组40.0%,高SALT-M/低MELD组42.9%,低SALT-M/高MELD组73.8%,低SALT-M/低MELD组63.7%(p<0.001)。
  • ACLF 3级患者中,高SALT-M组移植后死亡率为39.4%,低SALT-M组为63.1%(p=0.018)。

关键数值与推荐

  • SALT-M评分截断值为≥20,MELD评分截断值为≥30。
  • SALT-M预测1年移植后生存的AUROC为0.691,c-index为0.650。

临床怎么用

  • 作者认为,严重ACLF患者的移植可行性可基于SALT-M评分判定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute-on-chronic liver failure (ACLF) is a syndrome of patients with chronic liver disease presenting with multiple organ failures. Recently, Sundaram-ACLF-LT Mortality (SALT-M) score has been developed to predict 1-year post-liver transplantation mortality. We validated the SALT-M score in a large-volume, Asian single-centre cohort. AIMS: We validated the SALT-M score in a large-volume, Asian single-centre cohort. METHODS: We analysed 224 patients of ACLF grade 2-3. Area under the receiver operating characteristic curve (AUROC) and concordance index (c-index) were used to assess and compare the predictability of posttransplant mortality of SALT-M and other scores. Moreover, we compared the survivals of patients with high and low SALT-M, in conjunction with MELD score and ACLF grade. RESULTS: The AUROC for prediction of 1-year post-LT survival was higher in SALT-M (0.691) than in MELD, MELD-Na, MELD 3.0 and delta-MELD. Similarly, the c-index of the SALT-M (0.650) was higher than aforementioned MELD systems. When categorised by the cut-off of SALT-M ≥ 20 and MELD ≥ 30, patients with high SALT-M exhibited lower post-LT survival than those with low SALT-M scores regardless of high or low MELD (40.0% for high SALT-M/high MELD vs. 42.9% for high SALT-M/low MELD vs. 73.8% for low SALT-M/high MELD vs. 63.7% for low SALT-M/low MELD, p < 0.001). In patients with ACLF grade 3, SALT-M effectively stratified the posttransplant mortality (39.4% for high SALT-M vs. 63.1% for low SALT-M, p = 0.018). CONCLUSIONS: SALT-M outperformed previous MELD systems for predicting posttransplant mortality in Asian LT cohort with severe ACLF. Transplantability for patients with severe ACLF could be determined based on SALT-M.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim K, Yim SH, Lee JG, et al. Robust Predictive Performance of the SALT-M Score for Clinical Outcomes in Asian Patients With Acute-on-Chronic Liver Failure. Aliment Pharmacol Ther. 2024. PMID: 39392334. doi:10.1111/apt.18335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。